SLC5A2 and heart failure: Internationally, a cross-sectional analysis of diabetic patients within a British general practice research database found only 11.0% of the population (N = 242,624) were prescribed an SGLT2 inhibitor of which just 4.3% possessed a comorbid heart failure diagnosis [49].